These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34231117)

  • 1. Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy.
    De Gregori S; De Silvestri A; Molinaro MD; Monzillo V; Biscarini S; Colaneri M; Gallazzi I; Bartoli A; Bruno R; Seminari E
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):547-554. PubMed ID: 34231117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Rose WE; Leonard SN; Rybak MJ
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3061-7. PubMed ID: 18591272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ; Barber KE; Ireland CE; Rybak MJ
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia.
    Pea F; Crapis M; Cojutti P; Bassetti M
    Infection; 2014 Feb; 42(1):207-10. PubMed ID: 23884723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A High Daptomycin Dose Is Associated with Better Bacterial Clearance in Infections Caused by Vancomycin-Resistant Enterococcus faecium Regardless of Daptomycin Minimum Inhibitory Concentration in a Rat Infective Endocarditis Model.
    Wang JT; Yang CJ; Yang JL; Lin SW; Chuang YC; Sheng WH; Chen YC; Chang SC
    Microbiol Spectr; 2022 Oct; 10(5):e0255122. PubMed ID: 36190402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies.
    Rose WE; Rybak MJ; Kaatz GW
    J Antimicrob Chemother; 2007 Aug; 60(2):334-40. PubMed ID: 17540670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis.
    Cervera C; Castañeda X; de la Maria CG; del Rio A; Moreno A; Soy D; Pericas JM; Falces C; Armero Y; Almela M; Ninot S; Pare JC; Mestres CA; Gatell JM; Marco F; Miro JM;
    Clin Infect Dis; 2014 Jun; 58(12):1668-75. PubMed ID: 24647021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.
    Louie A; Kaw P; Liu W; Jumbe N; Miller MH; Drusano GL
    Antimicrob Agents Chemother; 2001 Mar; 45(3):845-51. PubMed ID: 11181370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of High Vs Standard Daptomycin Doses Examined in Chinese Patients With Severe Burn Injuries by Pharmacokinetic Evaluation.
    Huang Y; Lv G; Hu L; Wu Y; Guo N; Zhu Y; Ding L; Li Q; Liu S; Yang Y; Shao H
    J Burn Care Res; 2020 May; 41(3):705-713. PubMed ID: 32006005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between pharmacokinetic/pharmacodynamic indices and clinical outcomes in Japanese patients with skin and soft tissue infections treated with daptomycin: analysis of a phase III study.
    Takesue Y; Mikamo H; Kusachi S; Watanabe S; Takahashi K; Yoshinari T; Ishii M; Aikawa N
    Diagn Microbiol Infect Dis; 2015 Sep; 83(1):77-81. PubMed ID: 26072149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species.
    DeRyke CA; Sutherland C; Zhang B; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3529-34. PubMed ID: 17065618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
    da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV
    BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
    Chambers HF; Basuino L; Diep BA; Steenbergen J; Zhang S; Tattevin P; Alder J
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1463-7. PubMed ID: 19171803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
    Marco F; de la Mària CG; Armero Y; Amat E; Soy D; Moreno A; del Río A; Almela M; Mestres CA; Gatell JM; Jiménez de Anta MT; Miró JM;
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2538-43. PubMed ID: 18426900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating example.
    Pai MP; Russo A; Novelli A; Venditti M; Falcone M
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3162-7. PubMed ID: 24663017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic/Pharmacodynamic Analysis of Daptomycin Against Staphylococcus aureus and Enterococcus faecium in Pediatric Patients by Monte Carlo Simulation.
    Wei XC; Zhao MF; Li X; Xiao X
    J Clin Pharmacol; 2020 Jun; 60(6):768-774. PubMed ID: 32080861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis.
    Butterfield JM; Mueller BA; Patel N; Cardone KE; Grabe DW; Salama NN; Lodise TP
    Antimicrob Agents Chemother; 2013 Feb; 57(2):864-72. PubMed ID: 23208714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.
    Bhavnani SM; Ambrose PG; Hammel JP; Rubino CM; Drusano GL
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1600-7. PubMed ID: 26711755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observational study to determine the optimal dose of daptomycin based on pharmacokinetic/pharmacodynamic analysis.
    Yamada T; Ooi Y; Oda K; Shibata Y; Kawanishi F; Suzuki K; Nishihara M; Nakano T; Yoshida M; Uchida T; Katsumata T; Ukimura A
    J Infect Chemother; 2020 Apr; 26(4):379-384. PubMed ID: 31836287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.